GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010

21st Annual Meeting ASGCT, Chicago (IL), US

GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)

ARVO Annual Meeting, Honolulu, Hawaï, US

GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology

GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics

GenSight Biologics launches a capital increase of approximately €20 million